Audit of proton pump inhibitor (PPI) prescribing: Are NICE guidelines being followed? [5]

Clinical Medicine

Volumn 3, Issue 4, 2003, Pages 387-388

  Arasaradnam, R P ^a,b   Woodward, T ^b   Parrack, L ^c   Bartlett, J ^c   Bolton, R P ^b  

^a SHEFFIELD TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b DONCASTER ROYAL INFIRMARY   (United Kingdom)

^c DRI   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE;

GASTROENTEROLOGY; HUMAN; LETTER; PATIENT CARE; PEPTIC ULCER; PRACTICE GUIDELINE; PRESCRIPTION;

EID: 0041928052     PISSN: 14702118     EISSN: None     Source Type: Journal    
DOI: 10.7861/clinmedicine.3-4-387     Document Type: Letter

References (5)

1. Bardhan KD, Bianchi Porro G, Bose K, Daly M et al. A comparison of two different doses of omeprazole versus ranitidine in treatment of duodenal ulcers. J Clin Gastroenterol 1986;8:408-13.
2. National Institute for Clinical Excellence. Guidance on the use of PPI in the treatment of dyspepsia. London: NICE, 2000. www.nice.co.uk
3. Oddsson E, Gudjonsson H, Thjodleifsson B. Comparison between ranitidine and omeprazole for protection against gastroduodenal damage by naproxen. Scand J Gastroenterol 1992;27:1045-8.
4. Wurm P and Caestecker JD. Pharmacotherapy for chronic gastro-oesophageal reflux disease and Barrett's oesophagus. Expert Opin Pharmacother 2003 Jul;4(7):1049-61.
5. Neumann CS, Iqbal TH, Cooper BT. Long term continuous omeprazole treatment of patients with Barrett's oesophagus. Aliment Pharmacol Ther 1995;9(4):451-4.